Northland Capital Markets Initiates Coverage On Bloom Energy with Outperform Rating, Announces Price Target of $28
Northland Capital Markets analyst Donovan Schafer initiates coverage on Bloom Energy (NYSE:BE) with a Outperform rating and announces Price Target of $28.
Morgan Stanley Maintains Equal-Weight on Bloom Energy, Lowers Price Target to $21
Morgan Stanley maintains Bloom Energy (NYSE:BE) with a Equal-Weight and lowers the price target from $25 to $21.
Piper Sandler Assumes Bloom Energy at Neutral, Announces Price Target of $20
Piper Sandler analyst Kashy Harrison assumes Bloom Energy (NYSE:BE) with a Neutral rating and announces Price Target of $20.
Westinghouse, Bloom Energy Collaborate To Pursue Clean Hydrogen Production
Westinghouse Electric Company and Bloom Energy Corp (NYSE:BE) entered a Letter of Intent to pursue clean hydrogen generation in the commercial nuclear…
Westinghouse, Bloom Energy Sign Letter Of Intent To Accelerate Zero-Carbon, Large-Scale Hydrogen Production In The Nuclear Industry
Westinghouse Electric Company and Bloom Energy Corporation (NYSE:BE) today announced that they have entered into a Letter of Intent to pursue clean hydrogen production in the commercial nuclear power market. The
LSB Industries Picks Bloom Energy To Build 10 MW Solid Oxide Electrolyzer
Bloom Energy (NYSE:BE) and LSB Industries, Inc (NYSE:LXU) plan to install a 10 megawatt (MW) solid oxide electrolyzer at LSB’s Pryor, Oklahoma facility.…
55 Stocks Moving In Friday’s Mid-Day Session
Gainers
Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company.
24 Stocks Moving in Friday’s Pre-Market Session
Gainers
Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 35% to $3.47 in pre-market trading. Vinco Ventures set record date as May 18, 2022 For dividend of shares related to Cryptyde deal. The dividend is expected to be distributed on May 27, 2022.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.